Cargando…

Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression

Resistance to tyrosine kinase inhibitors (TKIs) results in tumor relapse and poor prognosis in patients with lung adenocarcinoma. TKI resistance caused by epidermal growth factor receptor (EGFR) mutations at T790M and c-Met amplification occurs through persistent activation of the MEK/ERK and PI3K/A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yao-Chen, Wu, De-Wei, Wu, Tzu-Chin, Wang, Lee, Chen, Chih-Yi, Lee, Huei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821048/ https://www.ncbi.nlm.nih.gov/pubmed/29483824 http://dx.doi.org/10.7150/ijbs.22209

Ejemplares similares

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
por: Song, Zhendong, et al.
Publicado: (2021)

Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma
por: Hu, Zhongqian, et al.
Publicado: (2017)

Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase
por: Markovics, Adrienn, et al.
Publicado: (2020)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2
por: Chen, Chuan, et al.
Publicado: (2015)

Eosinophil differentiation in the bone marrow is promoted by protein tyrosine phosphatase SHP2
por: Xia, L-x, et al.
Publicado: (2016)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization
por: Buck, Sara J. S., et al.
Publicado: (2022)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Determination of the molecular reach of the protein tyrosine phosphatase SHP-1
por: Clemens, Lara, et al.
Publicado: (2021)

The role of tyrosine phosphatase Shp2 in spermatogonial differentiation and spermatocyte meiosis
por: Li, Yang, et al.
Publicado: (2019)

Deletion of the tyrosine phosphatase Shp2 in Sertoli cells causes infertility in mice
por: Hu, Xiaopeng, et al.
Publicado: (2015)

The function of Shp2 tyrosine phosphatase in the dispersal of acetylcholine receptor clusters
por: Qian, Yueping K, et al.
Publicado: (2008)

Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis
por: Liu, Xia, et al.
Publicado: (2011)

Role of the Protein Tyrosine Phosphatase Shp2 in Homeostasis of the Intestinal Epithelium
por: Yamashita, Hironori, et al.
Publicado: (2014)

Inactivation of the tyrosine phosphatase SHP-2 drives vascular dysfunction in Sepsis
por: Heun, Yvonn, et al.
Publicado: (2019)

An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase
por: Anselmi, Massimiliano, et al.
Publicado: (2020)

The Tyrosine Phosphatase SHP2: A New Target for Insulin Resistance?
por: Saint-Laurent, Céline, et al.
Publicado: (2022)

Destabilization of the SHP2 and SHP1 protein tyrosine phosphatase domains by a non-conserved “backdoor” cysteine
por: Yarnall, Matthew T.N., et al.
Publicado: (2022)

A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma
por: Hu, Zhongqian, et al.
Publicado: (2015)

Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling
por: Tsai, Wan-Chen, et al.
Publicado: (2015)

Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
por: WANG, CHENGDE, et al.
Publicado: (2015)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

P1299: LOSS OF TYROSINE PHOSPHATASE SHP1 SENSITIZES DLBCL TO IBRUTINIB: A CANDIDATE PREDICTIVE BIOMARKER
por: Wang, Y. L., et al.
Publicado: (2022)

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells
por: Wu, D-W, et al.
Publicado: (2016)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

S100A9(+) MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB
por: Feng, Po-Hao, et al.
Publicado: (2018)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
por: Lee, Sanghun, et al.
Publicado: (2018)

Protein tyrosine phosphatase Shp2 deficiency in podocytes attenuates lipopolysaccharide-induced proteinuria
por: Hsu, Ming-Fo, et al.
Publicado: (2017)

Role of the Tyrosine Phosphatase SHP-2 in Mediating Adrenomedullin Proangiogenic Activity in Solid Tumors
por: Sigaud, Romain, et al.
Publicado: (2021)

Growth Factors, and Cytokines; Understanding the Role of Tyrosine Phosphatase SHP2 in Gametogenesis and Early Embryo Development
por: Idrees, Muhammad, et al.
Publicado: (2020)

Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB
por: Feng, Po-Hao, et al.
Publicado: (2018)

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
por: Tong, Xuexia, et al.
Publicado: (2019)

Loss of tyrosine phosphatase SHP2 activity promotes growth of colorectal carcinoma HCT-116 cells
por: Chen, Xin, et al.
Publicado: (2020)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells
por: Wang, Jun, et al.
Publicado: (2022)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

The Allosteric Site on SHP2’s Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules
por: Marsh-Armstrong, Brennan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_77itr39njrqvoqrkdul66u2hij